Helixgate

Helixgate

Uncategorized

STAT+: Pharma giant Takeda to lay off nearly 250 workers in latest job cutting

Takeda Pharmaceuticals will lay off nearly 250 workers in Cambridge, the state’s largest biopharma employer announced through a state filing.

The layoffs will begin in July, although some will take place later in the year or in 2027. All affected Massachusetts employees work at the company’s 500 Kendall St. location, according to the filing posted Friday.

The workforce reduction is part of a cost-saving plan approved by Takeda’s board of directors on March 25 that is expected to result in annual savings of about $1.25 billion by 2028, according to a company statement. Another 387 workers in other states may also be laid off as part of the plan.

Continue to STAT+ to read the full story…

Read More

Published

on

Takeda Pharmaceuticals will lay off nearly 250 workers in Cambridge, the state’s largest biopharma employer announced through a state filing.

The layoffs will begin in July, although some will take place later in the year or in 2027. All affected Massachusetts employees work at the company’s 500 Kendall St. location, according to the filing posted Friday.

The workforce reduction is part of a cost-saving plan approved by Takeda’s board of directors on March 25 that is expected to result in annual savings of about $1.25 billion by 2028, according to a company statement. Another 387 workers in other states may also be laid off as part of the plan.

Continue to STAT+ to read the full story…

Read More

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

Terns rebuffed a higher bid before selling to Merck

Regulatory filings show that Terns ultimately accepted an offer 15% lower than a previous proposal as four companies vied for rights to the coveted leukemia drug developer. 

Read More

Published

on

Regulatory filings show that Terns ultimately accepted an offer 15% lower than a previous proposal as four companies vied for rights to the coveted leukemia drug developer. 

Read More

Continue Reading

Uncategorized

STAT+: States looking to regulate use of chatbots

You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences. Sign up to get it delivered in your inbox every Tuesday and Thursday.

Good morning health tech readers!

Today, a deep dive into why America’s most powerful health insurer is looking more and more like a technology company. 

Continue to STAT+ to read the full story…

Read More

Published

on

You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences. Sign up to get it delivered in your inbox every Tuesday and Thursday.

Good morning health tech readers!

Today, a deep dive into why America’s most powerful health insurer is looking more and more like a technology company. 

Continue to STAT+ to read the full story…

Read More

Continue Reading

Uncategorized

ARPA-H selects three teams in $100M effort to repair and regrow ailing joints

Published

on

Three academic centers believe they may have discovered new ways to heal aging joints. Now the federal government is funding clinical trials to test these experimental regenerative medicines in osteoarthritis.
Teams from Duke University, the …

Continue Reading
Advertisement

Trending